Strides Arcolab receives USFDA approval for Lamivudine, Zidovudine tablets

15 May 2015 Evaluate

Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg. The US market for Lamivudine and Zidovudine Tablets is approximately $120 million, according to IMS data. The product will be manufactured at the company’s Oral dosage facility at Bangalore and marketed by Strides in the US Market. The product will be launched in the markets immediately.

Lamivudine and Zidovudine 150 mg/300 mg (generic version of generic version of Viiv’s Combivir) belong to a group of antiviral medicines, also known as antiretrovirals and is used with other antiretroviral medicines to treat HIV infection in adults and children. Lamivudine and Zidovudine 150 mg/300 mg Tablets reduces the amount of HIV in your body, and keeps it at a low level.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.


Strides Pharma Scien Share Price

937.75 -1.65 (-0.18%)
30-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1757.35
Dr. Reddys Lab 1254.65
Cipla 1223.05
Zydus Lifesciences 871.20
Lupin 2312.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×